‘The process may (or may not) be the product: trade secrets and COVID research’

“Like many economists, I was recently delighted to learn my training also makes me an epidemiologist, of sorts. Using these powers for good, I have turned my eye to the role of trade secrets in medical treatments and the implications for the COVID pandemic. Governments are scrambling to fund vaccines and medical research and access the subsequent innovations, ‘access’ that is governed in part by IP law. Access to medicines and pricing was already a contentious policy area before COVID; pharma has a trust problem …” (more)

[Nicola Searle, The IPKat, 3 August]

Leave a Reply